DAFNA Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

DAFNA Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-105,656	Closed	-$1.33M	–	84
2018 Q4	$1.33M	Buy	+105,656	New	+$1.46M	0.66%	39
2017 Q1	–	Sell	-66,968	Closed	-$689K	–	79
2016 Q4	$689K	Hold	66,968	–	–	0.61%	48
2016 Q3	$677K	Hold	66,968	–	–	0.47%	51
2016 Q2	$752K	Buy	+66,968	New	+$853K	0.6%	49

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DAFNA Capital Management's CNCE Position: Q1 2019 in Review

DAFNA Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2019, closing a stake of 105,656 shares — an estimated $1.33M sold.

DAFNA Capital Management first reported a position in CNCE in Q2 2016 and held it in 4 quarters. The position peaked at $1.33M in Q4 2018. 92 funds tracked by Wall St. Rank hold CNCE as of Q1 2019.

DAFNA Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
DAFNA Capital Management sold 105,656 Concert Pharmaceuticals, Inc. shares in Q1 2019, an estimated $1.33M.
DAFNA Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2016 and held it in 4 quarters.
DAFNA Capital Management's Concert Pharmaceuticals, Inc. position peaked at $1.33M in Q4 2018.
92 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2019.

Based on DAFNA Capital Management's 13F filing for Q1 2019, filed 15 May 2019.